Best practices in mitigating the risk of biotin interference with laboratory testing

Raffick Bowen, Raul Benavides, Jessica M. Colón-Franco, Brooke M. Katzman, Alagarraju Muthukumar, Hossein Sadrzadeh, Joely Straseski, Ursula Klause, Nam Tran

Research output: Contribution to journalReview article

Abstract

Dietary biotin intake does not typically result in blood biotin concentrations that exceed interference thresholds for in vitro diagnostic tests. However, recent trends of high-dose biotin supplements and clinical trials of very high biotin doses for patients with multiple sclerosis have increased concerns about biotin interference with immunoassays. Estimates of the prevalence of high biotin intake vary, and patients may be unaware that they are taking biotin. Since 2016, 92 cases of suspected biotin interference have been reported to the US Food and Drug Administration. Immunoassays at greatest risk from biotin interference include thyroid and reproductive hormones, cardiac, and immunosuppressive drug tests. Several case studies have highlighted the challenge of biotin interference with thyroid hormone assays and the potential misdiagnosis of Graves' disease. Biotin interference should be suspected when immunoassay test results are inconsistent with clinical information; a clinically relevant biotin interference happens when the blood biotin concentration is high and the assay is sensitive to biotin. We propose a best practice workflow for laboratory scientists to evaluate discrepant immunoassay results, comprising: (1) serial dilution; (2) retesting after biotin clearance and/or repeat testing on an alternate platform; and (3) confirmation of the presence of biotin using depletion protocols or direct measurement of biotin concentrations. Efforts to increase awareness and avoid patient misdiagnosis should focus on improving guidance from manufacturers and educating patients, healthcare professionals, and laboratory staff. Best practice guidance for laboratory staff and healthcare professionals would also provide much-needed information on the prevention, detection, and management of biotin interference.

Original languageEnglish (US)
JournalClinical Biochemistry
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Biotin
Practice Guidelines
Testing
Immunoassay
Diagnostic Errors
Thyroid Hormones
Assays
Blood
Delivery of Health Care
Laboratory Personnel
Workflow
Graves Disease
United States Food and Drug Administration
Immunosuppressive Agents
Routine Diagnostic Tests

Keywords

  • Biotin
  • Biotin interference
  • Biotin supplements
  • Immunoassay

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Bowen, R., Benavides, R., Colón-Franco, J. M., Katzman, B. M., Muthukumar, A., Sadrzadeh, H., ... Tran, N. (Accepted/In press). Best practices in mitigating the risk of biotin interference with laboratory testing. Clinical Biochemistry. https://doi.org/10.1016/j.clinbiochem.2019.08.012

Best practices in mitigating the risk of biotin interference with laboratory testing. / Bowen, Raffick; Benavides, Raul; Colón-Franco, Jessica M.; Katzman, Brooke M.; Muthukumar, Alagarraju; Sadrzadeh, Hossein; Straseski, Joely; Klause, Ursula; Tran, Nam.

In: Clinical Biochemistry, 01.01.2019.

Research output: Contribution to journalReview article

Bowen, R, Benavides, R, Colón-Franco, JM, Katzman, BM, Muthukumar, A, Sadrzadeh, H, Straseski, J, Klause, U & Tran, N 2019, 'Best practices in mitigating the risk of biotin interference with laboratory testing', Clinical Biochemistry. https://doi.org/10.1016/j.clinbiochem.2019.08.012
Bowen, Raffick ; Benavides, Raul ; Colón-Franco, Jessica M. ; Katzman, Brooke M. ; Muthukumar, Alagarraju ; Sadrzadeh, Hossein ; Straseski, Joely ; Klause, Ursula ; Tran, Nam. / Best practices in mitigating the risk of biotin interference with laboratory testing. In: Clinical Biochemistry. 2019.
@article{276dc2af1bb8466a9dbeff6c139d19e6,
title = "Best practices in mitigating the risk of biotin interference with laboratory testing",
abstract = "Dietary biotin intake does not typically result in blood biotin concentrations that exceed interference thresholds for in vitro diagnostic tests. However, recent trends of high-dose biotin supplements and clinical trials of very high biotin doses for patients with multiple sclerosis have increased concerns about biotin interference with immunoassays. Estimates of the prevalence of high biotin intake vary, and patients may be unaware that they are taking biotin. Since 2016, 92 cases of suspected biotin interference have been reported to the US Food and Drug Administration. Immunoassays at greatest risk from biotin interference include thyroid and reproductive hormones, cardiac, and immunosuppressive drug tests. Several case studies have highlighted the challenge of biotin interference with thyroid hormone assays and the potential misdiagnosis of Graves' disease. Biotin interference should be suspected when immunoassay test results are inconsistent with clinical information; a clinically relevant biotin interference happens when the blood biotin concentration is high and the assay is sensitive to biotin. We propose a best practice workflow for laboratory scientists to evaluate discrepant immunoassay results, comprising: (1) serial dilution; (2) retesting after biotin clearance and/or repeat testing on an alternate platform; and (3) confirmation of the presence of biotin using depletion protocols or direct measurement of biotin concentrations. Efforts to increase awareness and avoid patient misdiagnosis should focus on improving guidance from manufacturers and educating patients, healthcare professionals, and laboratory staff. Best practice guidance for laboratory staff and healthcare professionals would also provide much-needed information on the prevention, detection, and management of biotin interference.",
keywords = "Biotin, Biotin interference, Biotin supplements, Immunoassay",
author = "Raffick Bowen and Raul Benavides and Col{\'o}n-Franco, {Jessica M.} and Katzman, {Brooke M.} and Alagarraju Muthukumar and Hossein Sadrzadeh and Joely Straseski and Ursula Klause and Nam Tran",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.clinbiochem.2019.08.012",
language = "English (US)",
journal = "Clinical Biochemistry",
issn = "0009-9120",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Best practices in mitigating the risk of biotin interference with laboratory testing

AU - Bowen, Raffick

AU - Benavides, Raul

AU - Colón-Franco, Jessica M.

AU - Katzman, Brooke M.

AU - Muthukumar, Alagarraju

AU - Sadrzadeh, Hossein

AU - Straseski, Joely

AU - Klause, Ursula

AU - Tran, Nam

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Dietary biotin intake does not typically result in blood biotin concentrations that exceed interference thresholds for in vitro diagnostic tests. However, recent trends of high-dose biotin supplements and clinical trials of very high biotin doses for patients with multiple sclerosis have increased concerns about biotin interference with immunoassays. Estimates of the prevalence of high biotin intake vary, and patients may be unaware that they are taking biotin. Since 2016, 92 cases of suspected biotin interference have been reported to the US Food and Drug Administration. Immunoassays at greatest risk from biotin interference include thyroid and reproductive hormones, cardiac, and immunosuppressive drug tests. Several case studies have highlighted the challenge of biotin interference with thyroid hormone assays and the potential misdiagnosis of Graves' disease. Biotin interference should be suspected when immunoassay test results are inconsistent with clinical information; a clinically relevant biotin interference happens when the blood biotin concentration is high and the assay is sensitive to biotin. We propose a best practice workflow for laboratory scientists to evaluate discrepant immunoassay results, comprising: (1) serial dilution; (2) retesting after biotin clearance and/or repeat testing on an alternate platform; and (3) confirmation of the presence of biotin using depletion protocols or direct measurement of biotin concentrations. Efforts to increase awareness and avoid patient misdiagnosis should focus on improving guidance from manufacturers and educating patients, healthcare professionals, and laboratory staff. Best practice guidance for laboratory staff and healthcare professionals would also provide much-needed information on the prevention, detection, and management of biotin interference.

AB - Dietary biotin intake does not typically result in blood biotin concentrations that exceed interference thresholds for in vitro diagnostic tests. However, recent trends of high-dose biotin supplements and clinical trials of very high biotin doses for patients with multiple sclerosis have increased concerns about biotin interference with immunoassays. Estimates of the prevalence of high biotin intake vary, and patients may be unaware that they are taking biotin. Since 2016, 92 cases of suspected biotin interference have been reported to the US Food and Drug Administration. Immunoassays at greatest risk from biotin interference include thyroid and reproductive hormones, cardiac, and immunosuppressive drug tests. Several case studies have highlighted the challenge of biotin interference with thyroid hormone assays and the potential misdiagnosis of Graves' disease. Biotin interference should be suspected when immunoassay test results are inconsistent with clinical information; a clinically relevant biotin interference happens when the blood biotin concentration is high and the assay is sensitive to biotin. We propose a best practice workflow for laboratory scientists to evaluate discrepant immunoassay results, comprising: (1) serial dilution; (2) retesting after biotin clearance and/or repeat testing on an alternate platform; and (3) confirmation of the presence of biotin using depletion protocols or direct measurement of biotin concentrations. Efforts to increase awareness and avoid patient misdiagnosis should focus on improving guidance from manufacturers and educating patients, healthcare professionals, and laboratory staff. Best practice guidance for laboratory staff and healthcare professionals would also provide much-needed information on the prevention, detection, and management of biotin interference.

KW - Biotin

KW - Biotin interference

KW - Biotin supplements

KW - Immunoassay

UR - http://www.scopus.com/inward/record.url?scp=85071568724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071568724&partnerID=8YFLogxK

U2 - 10.1016/j.clinbiochem.2019.08.012

DO - 10.1016/j.clinbiochem.2019.08.012

M3 - Review article

JO - Clinical Biochemistry

JF - Clinical Biochemistry

SN - 0009-9120

ER -